A retrospective drug use evaluation (DUE) study on filgrastim was conducted by reviewing patients charts following criteria for drug use evaluation established by American Society Hospital Pharmacy and add to the standard indicators of ministry of Health & Wellfare by Korean Government. Total 33 charts of inpatients treated with filgrastim in Korea University Anam Hospital from jan. 1, 1995 to July 30, 1995 were retrospectively reviewed.
As a results, 33cases(100%) met with the criteria for the justification of use. In analysis indicators including allergy test and complete blood count(CBC) monitoring showed the accepted levels 93.9%, 97%, respectively. In appropriated dose, 21.2% was documented 5mcg/㎏/day of the standard indicators of Am. S. Hosp. Pharm. And 48.5% to 50㎎/㎡/ day of the standard indicators of Ministry of Health & Wellfare by Korean Government. Indicator of filgrastim continued until patient achives absolute neutrophil count (ANC) of≥10,000cell/㎣by Am. S. Hosp. Pharm. was documented 15.2% and started with ANC of <500㎣ and discontinued to ≥1,000㎣ with Ministry of Health & Wellfare was documented 15.2%. Bone pain of filgrastim complication was 12.1%. In Outcome analysis, decreased incidence and severity of infection was 75.8% and antineoplastics given 100% scheduled. Reduction in duration or severity of ANC nadir was documented 62%.
To be used effectively and safely, filgrastim is recommended to be adjusted to a standard level of dosage and an use limit by Korean Government.
|